1,548 results on '"Vergote I"'
Search Results
2. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
3. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
4. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
5. Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer
6. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
7. The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
8. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
9. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
10. Safety and efficiency of performing transvaginal ultrasound-guided tru-cut biopsy for pelvic masses
11. Robot-assisted surgery for women with endometrial cancer: Surgical and oncologic outcomes within a Belgium gynaecological oncology group cohort
12. Curative effect of second curettage for treatment of gestational trophoblastic disease - Results of the Belgian registry for gestational trophoblastic disease
13. Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors
14. Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort
15. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
16. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial
17. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D
18. A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel
19. Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
20. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer
21. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
22. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
23. Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12
24. Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting
25. Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer
26. Expression III: patients’ expectations and preferences regarding physician–patient relationship and clinical management—results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries
27. A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer
28. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
29. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial
30. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
31. SUCCOR Nodes: May Sentinel Node Biopsy Determine the Need for Adjuvant Treatment?
32. Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study
33. Statistical controversies in clinical research: the importance of importance
34. Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)
35. Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I
36. VALUE OF RADIOTHERAPY IN THE MANAGEMENT OF PAGETʼS DISEASE OF THE VULVA: A RETROSPECTIVE STUDY OF 31 PATIENTS: EP1193
37. SINGLE-CELL RNA-SEQUENCING OF 7 HGSOC CASES REVEALS MULTIPLE PROGNOSTIC CELL SUBTYPE: EP1126
38. INTESTINAL (SUB)OBSTRUCTION IN OVARIAN CANCER PATIENTS: MANAGEMENT, COMPLICATIONS AND SURVIVAL: EP877
39. PELVIC AND PARA-AORTIC VERSUS PELVIC LYMPHADENECTOMY IN INTERMEDIATE AND HIGH RISK ENDOMETRIAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS: EP601
40. OBSERVATIONAL STUDY OF THE BGOG ON THE RESULTS OF ROBOT-ASSISTED RADICAL HYSTERECTOMY FOR STAGE I CERVICAL CANCER IN BELGIUM: EP281
41. OUTCOME IN 186 PATIENTS WITH CERVICAL CANCER STAGE IB1 TREATED WITH RADICAL HYSTERECTOMY WITHOUT ADJUVANT RADIOCHEMOTHERAPY, UNLESS PRESENTING WITH METASTATIC LYMPH NODES: EP1218
42. Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe
43. Prognostic implications of lobular breast cancer histology: New insights from a single hospital cross-sectional study and SEER data
44. Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study
45. The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen
46. Preclinical Efficacy of TTFields and PARP Inhibitors in Ovarian Cancer Models
47. PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer
48. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma — Analysis of patient data in the prospective OVCAD study
49. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy
50. The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.